Non-hereditary retinoblastoma

Summary

Non-hereditary retinoblastoma (MONDO:0018161) is a disease. A subtype of retinoblastoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000	0.038	Europe	Not yet validated

Identifiers

Disease identifiers

Field	Value
Canonical name	non-hereditary retinoblastoma
Mondo ID	MONDO:0018161
EFO	EFO:0005717
Orphanet	357034
UMLS	C5680987
MedGen	1842255
GARD	0017545
Is cancer (heuristic)	no

Data availability: 1 cell line.

Disease family

This is a subtype of retinoblastoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › sensory system cancer › ocular cancer › retinal cancer › retinal cell cancer › retinoblastoma › non-hereditary retinoblastoma

Related subtypes (6): trilateral retinoblastoma, bilateral retinoblastoma, unilateral retinoblastoma, intraocular retinoblastoma, extraocular retinoblastoma, hereditary retinoblastoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.